ClinicalTrials.gg
Not yet recruitingNCT06373198Updated Apr 18, 2024

Implementation of a Re-engagement Program for Hepatitis C Patients Lost to Follow-up in Argentina.

An observational study in Hepatitis C Chronic and Hepatitis C, sponsored by Hospital El Cruce. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-18.

Sponsored by Hospital El Cruce · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years and older
Sex
All
01

Study summary

Hepatitis C virus (HCV) is a leading cause of morbidity and mortality worldwide. This infection continues to represent a major global public health concern. This is why the introduction of potent antivirals for the treatment of HCV has been one of the major breakthroughs of the current medical era.

From a public health perspective, HCV prevalence will be eliminated if the available treatment also targets those most likely to transmit the virus. Despite this scientific advance, a systematic review from the U.S. described that of the 43% of patients aware of their HCV diagnosis, only 16% started treatment. Clearly, the long-known barriers to accessing this treatment must be broken down in order to administer these effective antivirals. The World Health Organization (WHO) has set the ambitious goal of eliminating viral hepatitis as a public health threat by 2030. This goal is really difficult to achieve, especially in low and middle-income countries. Particularly in Argentina, there is a need to improve diagnosis, access to care, and treatment of viral hepatitis. The prospect of viral hepatitis elimination in our country is daunting due to the complexity of the health system and the cost of implementing different strategies. The most pragmatic approach would be to break down national elimination targets into smaller targets for individual populations, for which treatment and prevention interventions can be delivered more quickly and efficiently. This concept is known as micro-elimination. Focusing on micro-elimination of viral hepatitis means working to achieve the WHO target in specific subpopulations. Subpopulations known to have a higher prevalence of HCV infection include prisoners, people who inject drugs, and patients requiring hemodialysis, among others.

Currently, patient unawareness of HCV infection represents one of the major barriers to treatment. In many cases, the diagnosis of HCV was established many years ago and patients do not seek treatment probably because they do not recognize the urgency of treating this asymptomatic infection. It is our goal, then, to identify the group of individuals who have been diagnosed with HCV infection but are not currently undergoing regular visits with health care professionals. This strategy is now called re-linking to the medical care of patients with chronic HCV.

Read the detailed description

The protocol consists of implementing a strategy to contact patients with HCV who have been lost to follow-up. Establish a single model of confidential information management.

Population. From a cohort of patients, a non-probabilistic sampling of subjects meeting the eligibility criteria will be performed

Study Variables - Demographic data: age, gender

HCV-related data:

  • Hepatic complications such as hepatocarcinoma, ascites, encephalopathy, variceal hemorrhage and liver transplantation.
  • Extrahepatic manifestations such as non-Hodgkin\'s lymphoma, cryoglobulinemia, porphyria cutanea tarda, cardiovascular disease, diabetes mellitus.
  • Previous antiviral treatment with interferon-based or direct antiviral drugs.

Sources of information

  • Patient contact: phone call and/or e-mail.
  • Review of electronic medical records.

Patient contact strategy:

  • Patients identified as lost to follow-up will be contacted by telephone. Initially 3 calls will be made from Monday to Friday. If the patient is not located, he/she will be called on a Saturday and an e-mail will be sent (if available).

Possible outcomes after the intervention:

  • Not contacted despite implemented strategy
  • Death
  • Treated at another center
  • Contacted and candidate for follow-up

Measurement and data logging:

A specific form will be used to record the data, which will later be entered into a computerized database for subsequent analysis of the information. The research physicians who will be blinded will collect the exposure variables included in the survey to the results. Data for each patient will be obtained from the computerized medical record. Those patients with chronic HCV and whose disease course is unknown will be contacted by telephone to evaluate the status of their disease and to offer them, eventually, medical follow-up in our institution.

Ethics and Good Clinical Practices. The study protocol has been developed according to national standards for ethical, legal and juridical requirements, established in the Ministerial Resolution 1480/11 and international standards according to STROBE guidelines and according to ethical criteria of the Helsinki Declaration 2013, Nuremberg Code, Universal Declaration on Human Genome and Human Rights approved by the UNESCO General Conference 1997. As well as according to GCP standards (Good Clinical Practice). The confidentiality of all the data of each individual will be strictly maintained by means of the following strategies: the enrollment of the name, full ID and date of birth will be avoided, and will be replaced by coded data for the identification of the consequent methodologies according to this protocol.

Schedule of activities

  • Medical records review phase: 6 months
  • Phase of telephone calls: 3 months
  • Results evaluation phase 3 months: end of the study and final variable measurements.

Expected results Describing, knowing, understanding the impact of the disease we expect to find a significant number of patients with chronic HCV who are lost to follow-up. Likewise, some of these patients will likely be in follow-up at other institutions.

02

Conditions studied

  • Hepatitis C Chronic
  • Hepatitis C

Keywords

  • viral hepatitis
  • treatment
  • direct antivirals agents
  • relink
  • linkage to care
03

In context

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

This study's planned enrollment of 800 is above the median of 282 across 211 observational studies indexed under Hepatitis C, Chronic.

Browse Hepatitis C, Chronic studies →

Lead sponsor

Hospital El Cruce is the lead sponsor of 15 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

HCV viremic patients treatment naive or experienced

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All of the following inclusion criteria must be met.
  • Over 18 years old
  • Diagnosis of chronic

Exclusion criteria

Exclusion Criteria:

  • no
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • i. Strategy to re-engage HCV patients in a high complex hospital with a network

    An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.

    Other: standard of care

Interventions

  • Otherstandard of care

    An evaluation of the positivity of the hepatitis C test will be carried out. Positive patients will be included in the follow-up and specific treatment will be requested to achieve a cure. Standard of care will be applied.

06

What researchers measure

Primary outcomes

  1. rate of relinked HCV patients

    Strategy to re-engage HCV patients in a high complex hospital with a network of medium and low complexity hospitals.

    Time frame: From Mayo 2024 to January 2025

  2. proportion of relinked patients who received antiviral treatment

    Strategy to re-engage HCV patients in a high complex hospital with a network of medium and low complexity hospitals.

    Time frame: From Mayo 2024 to January 2025

Secondary outcomes

  1. Evaluation and characteristics of the treatment established

    * Describe the evolution of patients with HCV under follow-up. * describe the evolution and characteristics of HCV patients lost to follow-up. * Evaluate the number of patients relinked who effectively start treatment * Evaluate sustained virologic response rates and long-term clinical outcomes in patients who initiate treatment. * To evaluate SVR 4

    Time frame: From Mayo 2024 to January 2025

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007 Oct 20;370(9596):1453-7. doi: 10.1016/S0140-6736(07)61602-X. PubMed 18064739 ↗
  • Mendizabal M, Thompson M, Gonzalez-Ballerga E, Anders M, Castro-Narro GE, Pessoa MG, Cheinquer H, Mezzano G, Palazzo A, Ridruejo E, Descalzi V, Velarde-Ruiz Velasco JA, Marciano S, Munoz L, Schinoni MI, Poniachik J, Perazzo R, Cerda E, Fuster F, Varon A, Ruiz Garcia S, Soza A, Cabrera C, Gomez-Aldana AJ, Beltran FM, Gerona S, Cocozzella D, Bessone F, Hernandez N, Alonso C, Ferreiro M, Antinucci F, Torre A, Moutinho BD, Coelho Borges S, Gomez F, Murga MD, Pinero F, Sotera GF, Ocampo JA, Cortes Mollinedo VA, Simian D, Silva MO. Implementation of a re-linkage to care strategy in patients with chronic hepatitis C who were lost to follow-up in Latin America. J Viral Hepat. 2023 Jan;30(1):56-63. doi: 10.1111/jvh.13758. Epub 2022 Oct 17. PubMed 36197907 ↗
  • Wansom T, Falade-Nwulia O, Sutcliffe CG, Mehta SH, Moore RD, Thomas DL, Sulkowski MS. Barriers to Hepatitis C Virus (HCV) Treatment Initiation in Patients With Human Immunodeficiency Virus/HCV Coinfection: Lessons From the Interferon Era. Open Forum Infect Dis. 2017 Feb 11;4(1):ofx024. doi: 10.1093/ofid/ofx024. eCollection 2017 Winter. PubMed 28480293 ↗
  • Lazarus JV, Wiktor S, Colombo M, Thursz M; EASL International Liver Foundation. Micro-elimination - A path to global elimination of hepatitis C. J Hepatol. 2017 Oct;67(4):665-666. doi: 10.1016/j.jhep.2017.06.033. Epub 2017 Jul 29. No abstract available. PubMed 28760329 ↗
  • Mendizabal M, Alonso C, Silva MO. Overcoming barriers to hepatitis C elimination. Frontline Gastroenterol. 2019 Jul;10(3):207-209. doi: 10.1136/flgastro-2018-101114. Epub 2019 Feb 1. No abstract available. PubMed 31288259 ↗
  • Yehia BR, Schranz AJ, Umscheid CA, Lo Re V 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014 Jul 2;9(7):e101554. doi: 10.1371/journal.pone.0101554. eCollection 2014. PubMed 24988388 ↗

Individual participant data

Plan to share: Yes — De-identified participant data underpinning the reported study results, including data used in analyses for text, tables, figures, and appendices, will be shared.

Supporting information: Study protocol

Time frame: January 2025-January 2026

Access criteria: Permission from the principal investigator is requested via email.

Data sharing details ↗ · www.hospitalelcruce.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2024; primary completion for Jul 2024, 2 months later.

Of 38 non-industry observational studies under Hepatitis C, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 110. This study's planned 2 months is below that.

Counting every sponsor, half of 72 studies reached it within 32 months; a quarter within 22 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2024
First posted
Apr 18, 2024
StartEst.
May 1, 2024
Primary completionEst.
Jul 1, 2024
CompletionEst.
Jan 15, 2025
Last update
Apr 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06373198
Lead sponsor
Hospital El Cruce
Collaborators
Gilead Sciences
Responsible party
Fernando Mario Cairo (Principal Investigator, Hospital El Cruce) — Principal investigator
First posted
Apr 18, 2024
Start date
May 1, 2024 (estimated)
Primary completion
Jul 1, 2024 (estimated)
Completion
Jan 15, 2025 (estimated)
Last update
Apr 18, 2024

Study contacts

Fernando m Cairo, MD
Contact
jefatura.TOS@hospitalelcruce.org
+544210-9000 ext. 2812
Ignacio E Roca, MD
Contact
ignacioeroca@gmail.com
+544210-9000 ext. 2814

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion